This is the first work to show the activation of ROS/JNK pathway by Gli treatment in HCC cells, and identifying candidate agents activating ROS/JNK pathway may be a new strategy for HCC chemotherapy. This evidence concerns the gene GLI1 and hepatocellular carcinoma.